A Study of WF 10 IV Solution in Patients With Advanced HIV Disease
Phase 2
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002152
- Lead Sponsor
- Oxo Chemie GmbH
- Brief Summary
The purpose of this study is to see if it is safe and effective to give WF 10 (TCDO) to patients with advanced HIV disease who cannot or will not take zidovudine, didanosine, zalcitabine, or stavudine. This study also examines how TCDO affects the levels of HIV in the body. TCDO is a solution delivered through a vein.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Nashville Health Management Foundation / Vanderbilt Univ
🇺🇸Nashville, Tennessee, United States